These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 37193249)

  • 81. Association of a novel 27-gene immuno-oncology assay with efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer.
    Ranganath H; Jain AL; Smith JR; Ryder J; Chaudry A; Miller E; Hare F; Valasareddy P; Seitz RS; Hout DR; Varga MG; Schweitzer BL; Nielsen TJ; Mullins J; Ross DT; Gandara DR; Vidal GA
    BMC Cancer; 2022 Apr; 22(1):407. PubMed ID: 35421940
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.
    Miao K; Zhang X; Wang H; Si X; Ni J; Zhong W; Zhao J; Xu Y; Chen M; Pan R; Wang M; Zhang L
    Front Immunol; 2022; 13():912180. PubMed ID: 35844502
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Treatment and Survival in Advanced Non-Small Cell Lung Cancer, Urothelial, Ovarian, Gastric and Kidney Cancer: A Nationwide Comprehensive Evaluation.
    Sørup S; Darvalics B; Khalil AA; Nordsmark M; Hæe M; Donskov F; Agerbæk M; Russo L; Oksen D; Boutmy E; Verpillat P; Cronin-Fenton D
    Clin Epidemiol; 2021; 13():871-882. PubMed ID: 34588817
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Integration of longitudinal deep-radiomics and clinical data improves the prediction of durable benefits to anti-PD-1/PD-L1 immunotherapy in advanced NSCLC patients.
    Farina B; Guerra ADR; Bermejo-Peláez D; Miras CP; Peral AA; Madueño GG; Jaime JC; Vilalta-Lacarra A; Pérez JR; Muñoz-Barrutia A; Peces-Barba GR; Maceiras LS; Gil-Bazo I; Gómez MD; Ledesma-Carbayo MJ
    J Transl Med; 2023 Mar; 21(1):174. PubMed ID: 36872371
    [TBL] [Abstract][Full Text] [Related]  

  • 85. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
    Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
    Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
    [No Abstract]   [Full Text] [Related]  

  • 86. Loss of BLK expression as a potential predictor of poor prognosis and immune checkpoint blockade response in NSCLC and contribute to tumor progression.
    Xu Y; Xu J; Qiao R; Zhong H; Xia J; Zhong R
    Transl Oncol; 2023 Jul; 33():101671. PubMed ID: 37068401
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Anoikis-related CTNND1 is associated with immuno-suppressive tumor microenvironment and predicts unfavorable immunotherapeutic outcome in non-small cell lung cancer.
    Ni Y; Jiang M; Wu Y; Xiao P; Wu A; Xia W; Tang C; Yang X; Tian K; Chen H; Huang R
    J Cancer; 2024; 15(2):317-331. PubMed ID: 38169514
    [No Abstract]   [Full Text] [Related]  

  • 88. Guanylate binding protein 4 shapes an inflamed tumor microenvironment and identifies immuno-hot tumors.
    Zhou W; Yeerkenbieke G; Zhang Y; Zhou M; Li J
    J Cancer Res Clin Oncol; 2024 Feb; 150(2):90. PubMed ID: 38347243
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Immune-Omics Networks of
    Ye Q; Singh S; Qian PR; Guo NL
    Cancers (Basel); 2021 Aug; 13(17):. PubMed ID: 34503105
    [TBL] [Abstract][Full Text] [Related]  

  • 90. HK3 is correlated with immune infiltrates and predicts response to immunotherapy in non-small cell lung cancer.
    Tuo Z; Zheng X; Zong Y; Li J; Zou C; Lv Y; Liu J
    Clin Transl Med; 2020 Jan; 10(1):319-330. PubMed ID: 32508023
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Immunoreactive Microenvironment Modulator GBP5 Suppresses Ovarian Cancer Progression by Inducing Canonical Pyroptosis.
    Zou C; Shen J; Xu F; Ye Y; Wu Y; Xu S
    J Cancer; 2024; 15(11):3510-3530. PubMed ID: 38817865
    [TBL] [Abstract][Full Text] [Related]  

  • 92. A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.
    Li W; Wan L
    PLoS One; 2023; 18(6):e0286595. PubMed ID: 37262075
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
    Wu L; Zhang Z; Bai M; Yan Y; Yu J; Xu Y
    Cell Commun Signal; 2023 May; 21(1):119. PubMed ID: 37221584
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The Cost-Effectiveness of Sugemalimab Plus Chemotherapy as First-Line Treatment for Metastatic Squamous and Non-squamous NSCLC in China.
    Cheng R; Zhou Z; Liu Q
    Adv Ther; 2023 Oct; 40(10):4298-4309. PubMed ID: 37453992
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions.
    Zayed S; Louie AV; Breadner DA; Palma DA; Correa RJM
    Ther Adv Med Oncol; 2023; 15():17588359231183668. PubMed ID: 37435562
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The expression panel of CXCL9, GBP5, and IFNG is a potential pan-cancer biomarker to predict immunotherapy response.
    Wang J; Zhou Y; Yang Y; Wu Z
    Am J Transl Res; 2023; 15(6):3960-3975. PubMed ID: 37434847
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Crystal structures reveal nucleotide-induced conformational changes in G motifs and distal regions in guanylate-binding protein 2.
    Roy S; Wang B; Tian Y; Yin Q
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425906
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Interim survival analysis of the randomized phase III GEMSTONE-302 trial: sugemalimab or placebo plus chemotherapy as first-line treatment for metastatic NSCLC.
    Zhou C; Wang Z; Sun M; Cao L; Ma Z; Wu R; Yu Y; Yao W; Sun S; Chen J; Zhuang W; Cui J; Chen X; Lu Y; Shen H; Hu C; Liu J; Liu Y; Wang M; Li X; Sun P; Shu Y; Zhou J; Li J; Gu K; Wang C; Zhao H; Zhang Y; Liu C; Wang J; Chen R; Qin M; Wang H; Yang J
    Nat Cancer; 2023 Jun; 4(6):860-871. PubMed ID: 37322367
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Total T Cell Density and Expression of T Memory Stem Cell Markers are Associated with Better Prognosis in Colon Cancer.
    Ding J; Wang H; Hou R; Shi Y; Fan H; Li Y; Mei J; Zhang Q; Ruan T; Xu J
    Int J Gen Med; 2023; 16():2285-2294. PubMed ID: 37304906
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Human GBP1 Is Involved in the Repair of Damaged Phagosomes/Endolysosomes.
    Buijze H; Brinkmann V; Hurwitz R; Dorhoi A; Kaufmann SHE; Pei G
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298652
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.